ClinicalTrials.gg
CompletedNCT03571672BENEFIT1Updated Dec 17, 2020Results posted

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

A Phase 3 interventional study of DEFINITY in Cardiac Disease, sponsored by Lantheus Medical Imaging. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 646 studies in Heart Diseases with a site in United States — 93 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.

Enrollment
221st of 430
153 · median 161
Started
2018
with 26 others
Phase 3
63 of 646
2 open now
Registered
439th of 646
by date

Among the 646 studies in Heart Diseases with a site in United States, this one is the 221st largest by enrollment of the 430 interventional ones that give a count, is one of 27 that started in 2018, is one of 63 in phase 3, and was the 439th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

93 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 181 Heart Diseases studies recruiting now, 128 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 32 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 646 studies in Heart Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.

03

Conditions studied

  • Cardiac Disease

Browse trials for

Keywords

  • Left Ventricular Ejection Fraction
  • DEFINITY
  • Enhanced Echocardiogram
  • Cardiac Magnetic Resonance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age in sinus rhythm
  2. Able to communicate effectively with trial personnel
  3. Has undergone a 2D Echo with or without contrast obtained within 6 months prior to enrollment (Day 0)
  4. Has provided signed after receiving a verbal and written explanation of this clinical trial -

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating. All women of child bearing potential [] must have a negative urine pregnancy test at screening regardless of use history.
  2. Women of child-bearing potential are excluded unless they:

    1. are defined as amenorrhea ≥ 12 consecutive months, OR
    2. have undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), OR
    3. have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to DEFINITY® dose administration and be willing to continue using the same method for the duration of the study.
  3. Current illness or pathology that would prevent undergoing product administration due to a significant safety risk to the patient.
  4. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg).
  5. Unstable cardiovascular status defined as:

    1. myocardial infarction or unstable angina pectoris within 6 months prior to enrollment/DEFINITY® dose administration day
    2. or stroke within 3 months prior to DEFINITY® dose administration
    3. symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
    4. congenital heart defects
    5. current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise
    6. acute pulmonary embolus or pulmonary infarction
    7. acute myocarditis or pericarditis
    8. acute aortic dissection
    9. atrial fibrillation
  6. any major surgery within 4 weeks prior to screening
  7. known to undergoing CMR or claustrophobia
  8. participation in any investigational drug, device, or placebo study within 30 days prior to screening
  9. known to perflutren, or any of the in DEFINITY®
  10. prisoners or those who are subject to compulsory detention or involuntary incarceration for treatment of either a psychiatric or physical illness (e.g., infectious disease) -
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    DEFINITY

    Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound

    Drug: DEFINITY

Interventions

  • All subjects will receive a single dose of DEFINITY®

06

What researchers measure

Primary outcomes

  1. Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader

    Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using Definity contrast-enhanced over unenhanced echocardiography by comparing LVEF Percentage Differences from CMR measured by 3 independent blinded image readers.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

Secondary outcomes

  1. Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Suboptimal Echocardiograms

    Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent readers.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  2. Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers

    Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  3. Secondary Objective 3: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers

    Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic and systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  4. Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

    Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

  5. Secondary Objective 5: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

    Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

    Time frame: Up to 30 days between day of echocardiograms and CMR imaging

07

Results

Posted Dec 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneDefinity
Started153
Completed148
Not completed5

Outcome measures

PrimaryAbsolute Value of LVEF Percentage Differences From CMR by Blinded Reader

Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using Definity contrast-enhanced over unenhanced echocardiography by comparing LVEF Percentage Differences from CMR measured by 3 independent blinded image readers.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced6.10 ± 5.3196.38 ± 5.2274.93 ± 4.288
Echo Unenhanced6.18 ± 5.3006.61 ± 5.2565.36 ± 4.498
Statistical analysis
  • Blinded Reader 1 · t-test, 2 sided · p = 0.868 · Mean difference (final values): -0.08Paired t-test
  • Blinded Reader 2 · t-test, 2 sided · p = 0.606 · Mean difference (final values): -0.23Paired t-test
  • Blinded Reader 3 · t-test, 2 sided · p = 0.224 · Mean difference (final values): -0.43Paired t-test
SecondarySecondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Suboptimal Echocardiograms

Demonstrate improvement in accuracy in left ventricular ejection fraction (LVEF) assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms by comparing LVEF percentage differences from CMR measured by 3 independent readers.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 1: Absolute Value of LVEF Percentage Differences From CMR by Blinded Reader for Suboptimal Echocardiograms
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced7.48 ± 6.2287.16 ± 6.3375.71 ± 5.293
Echo Unenhanced7.16 ± 6.1847.12 ± 5.3815.89 ± 4.523
Statistical analysis
  • Blinded Reader 1 · t-test, 2 sided · p = 0.715 · Mean difference (final values): 0.32Paired t-test
  • Blinded Reader 2 · t-test, 2 sided · p = 0.956 · Mean difference (final values): 0.05Paired t-test
  • Blinded Reader 3 · t-test, 2 sided · p = 0.771 · Mean difference (final values): -0.17Paired t-test
SecondarySecondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers

Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 2: Absolute Value LVEF Percentage Differences From CMR Between Blinded Readers
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced6.10 ± 5.3196.38 ± 5.2274.93 ± 4.288
Echo Unenhanced6.18 ± 0.1646.61 ± 5.2565.36 ± 4.498
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.959 · 95% CI 0.944 to 0.970
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.950 · 95% CI 0.931 to 0.964
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.957 · 95% CI 0.941 to 0.969
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.934 · 95% CI 0.909 to 0.952
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.961 · 95% CI 0.946 to 0.972
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.937 · 95% CI 0.913 to 0.954
SecondarySecondary Objective 3: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers

Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic and systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · mL
Secondary Objective 3: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers
mLBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced End Diastolic52.31 ± 35.72646.57 ± 33.78539.37 ± 26.206
Echo Unenhanced End Diastolic58.02 ± 38.48356.65 ± 37.76648.07 ± 31.620
Echo Enhanced End Systolic33.56 ± 28.64129.93 ± 25.84526.01 ± 20.740
Echo Unenhanced End Systolic37.53 ± 30.01633.51 ± 28.07930.72 ± 23.534
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.988 · 95% CI 0.984 to 0.992
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.986 · 95% CI 0.981 to 0.990
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.960 · 95% CI 0.945 to 0.971
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.925 · 95% CI 0.897 to 0.945
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.970 · 95% CI 0.958 to 0.978
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.909 · 95% CI 0.876 to 0.934
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.989 · 95% CI 0.984 to 0.992
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.985 · 95% CI 0.979 to 0.989
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.973 · 95% CI 0.962 to 0.980
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.947 · 95% CI 0.927 to 0.961
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.977 · 95% CI 0.969 to 0.984
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.937 · 95% CI 0.914 to 0.954
SecondarySecondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing LVEF Percentage Differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · Percent Ejection Fraction
Secondary Objective 4: Absolute Value of LVEF Percentage Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
Percent Ejection FractionBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced7.48 ± 6.2287.16 ± 6.3375.71 ± 5.293
Echo Unenhanced7.16 ± 6.1847.12 ± 5.3815.89 ± 4.523
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.945 · 95% CI 0.909 to 0.967
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.917 · 95% CI 0.864 to 0.950
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.939 · 95% CI 0.900 to 0.963
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.894 · 95% CI 0.827 to 0.935
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.952 · 95% CI 0.920 to 0.971
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.900 · 95% CI 0.838 to 0.939
SecondarySecondary Objective 5: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms

Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volumes using DEFINITY® contrast-enhanced versus unenhanced echocardiography by comparing end-diastolic and systolic volume differences from CMR between 3 independent blinded readers in subjects with suboptimal echocardiograms.

Time frame:
Up to 30 days between day of echocardiograms and CMR imaging
Reported as:
Mean · mL
Secondary Objective 5: Absolute Value End-Diastolic and Systolic Volume Differences From CMR Between Blinded Readers for Suboptimal Echocardiograms
mLBlinded Reader 1Blinded Reader 2Blinded Reader 3
Echo Enhanced End Diastolic62.34 ± 40.03554.68 ± 37.57145.44 ± 29.702
Echo Unenhanced End Diastolic65.45 ± 43.22763.25 ± 41.70053.77 ± 34.210
Echo Enhanced End Systolic39.52 ± 29.71234.00 ± 26.95530.12 ± 22.174
Echo Unenhanced End Systolic39.45 ± 33.30333.97 ± 29.23332.78 ± 24.522
Statistical analysis
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.976 · 95% CI 0.961 to 0.986
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.984 · 95% CI 0.974 to 0.991
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.933 · 95% CI 0.890 to 0.960
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.857 · 95% CI 0.770 to 0.912
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.948 · 95% CI 0.914 to 0.969
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.824 · 95% CI 0.721 to 0.892
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.982 · 95% CI 0.970 to 0.989
  • Blinded Reader 1 vs Blinded Reader 2 · Intra-class correlation coefficient: 0.974 · 95% CI 0.957 to 0.985
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.948 · 95% CI 0.915 to 0.969
  • Blinded Reader 1 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.890 · 95% CI 0.822 to 0.933
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.959 · 95% CI 0.932 to 0.975
  • Blinded Reader 2 vs Blinded Reader 3 · Intra-class correlation coefficient: 0.872 · 95% CI 0.794 to 0.922

Adverse events

Collected over Up to 12 days: Enrolled subjects were followed for adverse events and serious adverse events from the time the Informed Consent was signed at screening (Day -7 to Day 0) through 72+/- 24 hours after completion of Definity administration (Day 0).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Definity0/153 (0%)0/153 (0%)0/153 (0%)

Baseline characteristics

Baseline data are calculated based on Safety Population

Age, Categorical
Age, Categorical(Participants)Definity
<=18 years0
Between 18 and 65 years98
>=65 years55
Sex: Female, Male
Sex: Female, Male(Participants)Definity
Female51
Male102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Definity
Hispanic or Latino18
Not Hispanic or Latino135
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Definity
American Indian or Alaska Native2
Asian3
Native Hawaiian or Other Pacific Islander4
Black or African American37
White104
More than one race3
Unknown or Not Reported0
LVEF Group
LVEF Group(Participants)Definity
LVEF <30%35
LVEF 30-40%40
LVEF 41-50%39
LVEF >50%39
08

Study locations

9 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • University of California-San Diego
    San Diego, California 92037, United States
  • Alfieri Cardiology
    Wilmington, Delaware 19803, United States
  • Henry Ford Hospital
    Detroit, Michigan 48208, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • University Hospital/Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • West Virginia University Medical Center
    Morgantown, West Virginia 26505, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2019, 10 months.

Results were first posted in Dec 2020, 1 year 3 months after primary completion.

Of 32 phase 3 interventional studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2018
First posted
Jun 27, 2018
StartActual
Oct 24, 2018
Primary completionActual
Aug 30, 2019
CompletionActual
Aug 30, 2019
Results first posted
Dec 17, 2020
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03571672
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Oct 24, 2018
Primary completion
Aug 30, 2019
Completion
Aug 30, 2019
Results posted
Dec 17, 2020
Last update
Dec 17, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion